Is AstraZeneca plc a falling knife to catch after dropping 15% today?

AstraZeneca plc (LON: AZN) could be one of best bargains of the FTSE 100 (INDEXFTSE: UKX) right now.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I didn’t expect to wake up this morning to see a 15% drop in the AstraZeneca (LSE: AZN) share price, but that’s what’s happened. The price has dipped to 4,282p, bringing this year’s bullishness to an abrupt halt. 

One of the company’s big new hopes, a study into a new cancer drug candidate that was hoped to become a first-line treatment as an alternative to chemotherapy, has disappointed. The trial showed that the drug combination “did not meet a primary endpoint of progression-free survival compared to chemotherapy” — in other words, there was no benefit over chemotherapy.

Rumours that chief executive Pascal Soriot is set to leave the company whose strategic turnaround he has been pioneering haven’t helped, and he so far appears not to have directly commented on the suggestion.

Interim results seem like a bit of a distraction right now, but they’re in line with full-year forecasts. Revenue for the half dropped by 11% (9% at constant exchange rates), though core operating profit rose by 7% with core earnings per share up 5%. The interim dividend was maintained at 90 US cents per share with “guidance for 2017 reiterated“.

How bad is it?

How much of a blow is the trial failure? Seen against the background of AstraZeneca’s wide drugs pipeline, I don’t see it as the catastrophe that some do. Even after today’s drop, the shares are still up 39% over the past five years of transformation, and dividends have been going steady at better than 4%.

With the shares on a forward P/E of 15, and a drugs pipeline that’s only just starting to mature, AstraZeneca is seriously starting to look like a takeover candidate — and even the departure of Mr Soriot shouldn’t dent that too much, with most of his refocusing work already done. 

A good buying opportunity, I reckon.

Recovery pick

Looking at another recovering FTSE 100 company whose share price revival has faltered a little of late, I’m starting to like the look of Anglo American (LSE: AAL).  The strong share price gains of 2016 started to reverse in 2017, but in the past month we’ve been seeing the signs of another bull run — and I reckon it’s set to continue over the longer term. 

My optimism was boosted Thursday by the firm’s first-half results, which heralded the return of the much-missed dividend, after $2.7bn in free cash flow helped to get net debt down to $6.2bn. Sure, $6.2bn isn’t small change, but that’s almost a 50% reduction since the same time last year, with gearing at a relatively modest 19% and the net debt figure representing around 80% of annualised EBITDA.

Dividends back

Chief executive Mark Cutifani spoke of “a further 20% increase in productivity, [and] a 68% increase in underlying EBITDA,” pointing to keen control of capital expenditure and improving prices as being the main drivers.

With a resumption of dividends “at a targeted level of 40% of underlying earnings” six months earlier than expected, amounting to 48 US cents for the half, full-year forecasts of a 3.8% yield are now looking unduly modest.

Even accounting for Anglo American’s still-high net debt levels, a forward P/E of only a little over seven based on the current year’s forecasts looks too low to me, and I’m seeing another FTSE 100 buying opportunity.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »